“Here’s how the initiative works: 23andMe customers can opt-in to the Fox Insight study, which includes data gleaned from patient surveys about the day-to-day lives of people living with the degenerative disorder (such as symptom onset, general health and diseases status, and other such metrics). The optional program then pools participants’ de-identified survey data with de-identified genetic data from 23andMe’s at-home DNA tests.”
“One major goal of the study is to give researchers and drug developers more insight into how Parkinson’s patients, who often have very different reactions to their disease, should be segmented for clinical purposes, and how their divergent experiences should inform medical advice, according to 23andMe. That could mean analyzing the interplay between environmental factors and genetics or other kinds of correlations that are difficult to assess without ‘real world’ data.”
Full Article: fortune.com/2019/04/29/mich...
Is Michael J Fox organization holding up key PD research?
Follow up with Survey Responses
As Parkinson’s patients wait, Fox Foundation and scientist feud over Nilotinib drug trial
23andMe MJFF genetics 🧬 sub-study
